We continue with the top 10 research updates of the past year, with a focus on lithium,

lumetepirone, and a German extract of lavender.

Welcome to the Carlet Psychiatry Podcast, keeping psychiatry honest since 2003.

I'm Chris Aiken, the editor-in-chief of the Carlatte Psychiatry Report.

And I'm Kelly Newsom, a psychiatric MP, and a dedicated reader of every issue.

If you want to follow along visually with this podcast, we have the slides with the data from the

studies at Chris AikenMD.com forward slash speaker requests.

They're right at the top of the page.

A few years ago, we asked Robert Post, founder of the Bipolar Collaborative Network,

what his top ten treatment was for bipolar disorder.

The three else, he replied, lithium,

Lomotrogen, and Larazidone. Today, we have research updates on a different set of Ls, lithium,

Lomiteperone, and lavender. I agree with Dr. Post, but I would rank lumeteperone close to

lorazidone in bipolar depression.

They are both among the better tolerated options there, and both have similar effect sizes.

Lomoteprone tends to cause more fatigue and dizziness, while Lerazodone causes more acathesia and nausea.

They both have evidence as monotherapy in depression,

that's unipolar depression, with mixed features, as well as bipolar depression with mixed

features, and both of them suffer from the same setback. Neither lorizodone nor Lomiteproen

are known to work in mania. But Larisodone has one advantage over

lumeteperone. It is generic. So that's regarding bipolar disorder, but our next study concerns

lumeteprone in unipolar depression, and it has changed how I use this medication.

...